Skip to main content
TipRanks
Go Ultimate75% OFF

Cartesian Therapeutics (RNAC) AI Stock Analysis

1,214 Followers
RNAC

Cartesian Therapeutics

(NASDAQ:RNAC)

Select Model
Rating:47Neutral
Price Target:$6.00â–¼(-1.32% Downside)
Action:reiterated
Date:11/05/26

The score is held down primarily by weak financial performance (shrinking revenue, large losses, and significant cash burn alongside negative equity). Technicals are also mixed-to-weak with the stock below key longer-term moving averages and a negative MACD. A notable offset is the positive corporate event around Descartes-08 retreatment data, but valuation support is limited given the company is loss-making and no dividend yield is provided.

Positive Factors
Differentiated RNA Cell TherapyCartesian’s transient mRNA approach is designed to engineer therapeutic cells without permanent genetic modification. This could provide a differentiated safety and flexibility profile versus permanently altered therapies, supporting continued development across autoimmune diseases and selected cancers.
Negative Factors
Pre-Commercial Business ModelCartesian remains pre-commercial, with no approved product or recurring product sales revenue. Its ability to fund operations therefore depends primarily on external financing and possible collaboration payments, leaving commercialization execution and future funding as central business risks.

Cartesian Therapeutics (RNAC) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%50%RNAC-14.97%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$185.46M
Dividend Yield
―
Average Volume (3M)
137.37K
Price to Earnings (P/E)
-1.2
Beta (1Y)
2.54
Revenue Growth
―
EPS Growth
―
Country
US
Employees
75
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Cartesian Therapeutics Business Overview & Revenue Model

Company Description

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cel...

How the Company Makes Money

Cartesian Therapeutics is a pre-commercial, clinical-stage biotechnology company. As of publicly available information up to my knowledge cutoff (2025-08), it does not have an approved product and therefore does not generate recurring product sales r...

Cartesian Therapeutics Financial Statement Overview

Summary

Weak fundamentals driven by steep revenue decline into TTM, heavy sustained losses (TTM net loss ~$129.5M), and significant ongoing cash burn (TTM operating cash flow about -$88.7M and negative free cash flow). Balance sheet is constrained by negative equity (TTM ~-$130.5M), increasing financing/dilution risk despite relatively modest absolute debt (~$10.1M TTM).

Income Statement

22Negative

Balance Sheet

28Negative

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.02M2.80M38.91M26.00M110.78M85.08M
Gross Profit1.02M2.80M38.91M26.00M108.74M85.08M
EBITDA-130.78M-136.54M-75.99M-235.03M39.09M-5.63M
Net Income-129.51M-130.30M-77.42M-219.71M35.38M-25.69M
Balance Sheet
Total Assets294.31M296.41M435.02M305.05M165.89M159.88M
Cash, Cash Equivalents and Short-Term Investments122.97M125.14M212.61M76.91M134.60M128.06M
Total Debt60.34M12.68M13.98M10.96M37.92M35.28M
Total Liabilities424.77M422.65M441.82M745.23M72.06M137.36M
Stockholders Equity-130.47M-126.24M-6.80M-440.18M93.83M22.52M
Cash Flow
Free Cash Flow-89.44M-79.39M-32.77M-51.37M-32.83M-61.47M
Operating Cash Flow-88.20M-73.94M-23.67M-51.16M-31.63M-60.38M
Investing Cash Flow-1.23M-5.45M-8.74M34.61M-15.00M-17.14M
Financing Cash Flow53.85M-8.05M168.43M-13.14M39.22M52.90M

Cartesian Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price6.08

Price Trends

50DMA7.08Negative
100DMA8.06Negative
200DMA7.61Negative

Market Momentum

MACD-0.15Positive
RSI38.57Neutral
STOCH9.47Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNAC, the sentiment is Negative. The current price of 6.08 is below the 20-day moving average (MA) of 6.58, below the 50-day MA of 7.08, and below the 200-day MA of 7.61, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 38.57 is Neutral, neither overbought nor oversold. The STOCH value of 9.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNAC.

Cartesian Therapeutics Risk Analysis

Cartesian Therapeutics disclosed 47 risk factors in its most recent earnings report. Cartesian Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Issuing additional equity securities may cause dilution to our stockholders.Q2, 2026
2.The terms of our Loan Agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our operating and financial flexibility.Q2, 2026
3.We have recorded a material amount of goodwill and indefinite-lived intangible assets in connection with the Merger. We may record impairment charges, which would adversely impact our financial position and results of operations.Q4, 2024

Cartesian Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RNAC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CLLSCLLS49Neutral$79.50M-1.68-94.14%―-0.11%-13.99%
IPSCIPSC49Neutral$297.82M-2.19-45.64%―-100.00%-97.48%
RNACRNAC47Neutral$185.46M-1.2497.73%―――
FATEFATE45Neutral$138.59M-1.09-73.92%―-33.45%21.90%
NKTXNKTX44Neutral$86.76M-0.70-48.58%――-24.79%
CABACABA41Neutral$239.45M-0.78-106.78%――43.51%

* Healthcare Sector Average

Performance Comparison

0%200%400%RNACFATECLLSCABANKTXIPSCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RNAC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RNACCartesian Therapeutics, Inc.6.08-1.54-20.21%
FATEFate Therapeutics Inc1.140.1211.76%
CLLSCellectis S.A.1.04-3.07-74.70%
CABACabaletta Bio, Inc.1.11-1.23-52.56%
NKTXNkarta, Inc.1.21-0.60-33.15%
IPSCCentury Therapeutics, Inc.1.641.15234.69%

Cartesian Therapeutics Corporate Events

Business Operations and Strategy

Cartesian Therapeutics Reports Encouraging Descartes-08 Retreatment Data

Positive
Sep 29, 2026

On September 29, 2026, Cartesian Therapeutics reported additional retreatment data from its Phase 2 trial of Descartes-08 in patients with generalized myasthenia gravis. In five patients who experienced symptom recurrence at least 12 months after an...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026